97 related articles for article (PubMed ID: 12681968)
1. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
[TBL] [Abstract][Full Text] [Related]
2. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
3. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
4. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib.
Drechsler M; Hildebrandt B; Kündgen A; Germing U; Royer-Pokora B
Ann Hematol; 2007 May; 86(5):353-4. PubMed ID: 17211520
[No Abstract] [Full Text] [Related]
5. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
[TBL] [Abstract][Full Text] [Related]
6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
7. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein.
Sjöblom T; Boureux A; Rönnstrand L; Heldin CH; Ghysdael J; Ostman A
Oncogene; 1999 Nov; 18(50):7055-62. PubMed ID: 10597306
[TBL] [Abstract][Full Text] [Related]
9. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
11. Tel/PDGFRbeta inhibits self-renewal and directs myelomonocytic differentiation of ES cells.
Dobbin E; Corrigan PM; Walsh CP; Welham MJ; Freeburn RW; Wheadon H
Leuk Res; 2008 Oct; 32(10):1554-64. PubMed ID: 18355917
[TBL] [Abstract][Full Text] [Related]
12. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
[TBL] [Abstract][Full Text] [Related]
13. Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta).
Bourgeade MF; Défachelles AS; Cayre YE
Blood; 1998 May; 91(9):3333-9. PubMed ID: 9558390
[TBL] [Abstract][Full Text] [Related]
14. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
15. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
Chen J; Wall NR; Kocher K; Duclos N; Fabbro D; Neuberg D; Griffin JD; Shi Y; Gilliland DG
J Clin Invest; 2004 Jun; 113(12):1784-91. PubMed ID: 15199413
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelomonocytic leukemia: myeloproliferative variant.
Onida F; Beran M
Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
[TBL] [Abstract][Full Text] [Related]
18. CMML: a biologically distinct myeloproliferative disease.
Cortes J
Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation.
Funakoshi-Tago M; Tago K; Nishizawa C; Takahashi K; Mashino T; Iwata S; Inoue H; Sonoda Y; Kasahara T
Biochem Pharmacol; 2008 Dec; 76(12):1681-93. PubMed ID: 18848530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
